Back to Browse Journals » Journal of Vascular Diagnostics and Interventions » Volume 2

Increased size of third ventricle in patients with multiple sclerosis and chronic cerebrospinal venous insufficiency

Authors d'Alessandro A, Mandolesi S, Niglio T, Orsini A, Di Cello P, Pelle F, Mora F, d'Alessandro A, Mandolesi D, Fedele F

Received 24 October 2013

Accepted for publication 30 April 2014

Published 17 September 2014 Volume 2014:2 Pages 91—97

DOI https://doi.org/10.2147/JVD.S56519

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Aldo d'Alessandro,1 Sandro Mandolesi,2 Tarcisio Niglio,6 Augusto Orsini,3 Pierfrancesco Di Cello,3–5 Fabio Pelle,5 Fabio Mora,3 Alessandro d'Alessandro,4 Dimitri Mandolesi,7 Francesco Fedele2

1Department of Angiology, T Masselli–Mascia Hospital, San Severo (FG), Italy; 2Department of Cardio-vascular and Respiratory Sciences, Nephrology and Geriatric, Sapienza University, Rome, Italy; 3Department of Vascular Surgery, Gioia Hospital, Sora (FR), Italy; 4Faculty of Medicine, Catholic University "Our Lady of Good Counsel", Tirana, Albania; 5Department of Surgery, Sapienza University, Rome, Italy; 6Istituto Superiore di Sanità, Rome, Italy; 7Medicina del Lavoro, Sapienza University, Rome, Italy

Objective: The aim of the present study was to assess the size of the third ventricle in a sample of patients with multiple sclerosis (MS) affected by chronic cerebrospinal venous insufficiency (CCSVI), versus size of the third ventricle in a healthy control group.
Background: CCSVI, a new nosological vascular pattern, has recently been associated with MS.
Methods: We enrolled 33 patients affected by MS (three in the primary progressive clinical course, 23 in the relapsing–remitting clinical course, and seven in the secondary–progressive clinical course). All patients had been affected by CCSVI and were tested using an echo color Doppler (ECD) imaging unit. The group of 33 affected by both MS and CCSVI (MS–CCSVI) was composed of 19 females and 14 males with a mean age of 40±10 years, from a minimum age of 20 years to a maximum age of 66 years, with a median of 40 years and a mode of 32 years. We compared the 33 MS–CCSVI patients with 33 healthy control subjects of similar sex and age. In the MS–CCSVI group, the MS clinical severity was expressed by expanded disability status scale (EDSS) score: light (19 patients, scoring 1, 2, or 3); medium (ten patients with a score of 4, 5, or 6), and severe (four patients with a score of 7, 8, or 9). The average duration of the MS was 10±7 years (from a minimum of 1 to a maximum of 26 years, with a median of 10 years and a mode of 1 year).
Results: In the MS–CCSVI group, the third ventricle diameter was 6.2±1.7 mm (from a minimum of 2.5 mm to a maximum of 9.2 mm, with a median of 6.3 mm, and a mode of 6.0 mm). Our data showed that 29 patients (88%) had an increase in third ventricle diameter, whereas only four patients (12%) had physiological size (less than 4 mm) comparable to all healthy control group subjects (27.28%). These results show that the increase in the third ventricle diameter could represent a criterion of positivity of neurological disease in patients with CCSVI.

Keywords: MS, CSSVI, increased size of the third ventricle
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Using the MEM-net program to report on mapping the EchoColorDoppler assessment for chronic cerebro spinal venous insufficiency

Mandolesi S, d'Alessandro A, Manconi E, Niglio T, Orsini A, Mandolesi D, d'Alessandro A, Fedele F

Journal of Vascular Diagnostics and Interventions 2014, 2:59-66

Published Date: 10 July 2014

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Is increasing the dose of Entecavir effective in partial virological responders?

Erturk A, Adnan Akdogan R, Parlak E, Cure E, Cumhur Cure M, Ozturk C

Drug Design, Development and Therapy 2014, 8:621-625

Published Date: 29 May 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010